Bonn University supports research staff in stem cell furore
This article was originally published in Clinica
The University of Bonn has dismissed criticism of two members of its staff, Professor Otmar Wiestler and Dr Oliver Brustle, who had voiced the hope of being able to import embryonic stem cells for research purposes (see Clinica No 962, p 5). In a public debate last week, the board of the faculty of medicine acknowledged that a factual discussion on research into both adult and embryonic stem cells was a necessity, but that personal attacks on its staff members were "unwarranted and discriminatory".
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.